Literature DB >> 22773606

Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Esteban Braggio1, Casey Philipsborn, Anne Novak, Lucy Hodge, Stephen Ansell, Rafael Fonseca.   

Abstract

Waldenström's macroglobulinemia is an indolent, lymphoproliferative disease, characterized by a heterogeneous lymphoplasmacytic bone marrow infiltrate and high immunoglobulin M production. While technological advances over the past several decades have dramatically improved the possibilities of studying the molecular basis of Waldenström's macroglobulinemia, the pathogenesis of the disease remains fragmented. Undoubtedly, research has been successful in uncovering underlying aberrations and deregulated mechanisms in this disease, providing useful information for identifying biomarkers for disease diagnosis, risk stratification and therapeutic intervention, but there is still a long way to go before the pathogenesis of Waldenström's macroglobulinemia is fully revealed. In addition, the low number of in vitro or in vivo models significantly challenges extensive analysis. In this manuscript, we review the molecular basis of this disease.

Entities:  

Mesh:

Year:  2012        PMID: 22773606      PMCID: PMC3436227          DOI: 10.3324/haematol.2012.068478

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  83 in total

1.  Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.

Authors:  R G Owen; S L Barrans; S J Richards; S J O'Connor; J A Child; L A Parapia; G J Morgan; A S Jack
Journal:  Am J Clin Pathol       Date:  2001-09       Impact factor: 2.493

2.  Origins of the malignant clone in typical Waldenstrom's macroglobulinemia.

Authors:  Surinder S Sahota; Francesco Forconi; Christian H Ottensmeier; Freda K Stevenson
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 3.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

4.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

5.  Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

Authors:  Sherine F Elsawa; Anne J Novak; Steven C Ziesmer; Luciana L Almada; Lucy S Hodge; Deanna M Grote; Thomas E Witzig; Martin E Fernandez-Zapico; Stephen M Ansell
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

6.  A SCID-hu in vivo model of human Waldenström macroglobulinemia.

Authors:  Pierfrancesco Tassone; Paola Neri; Jeffery L Kutok; Olivier Tournilhac; Daniel Ditzel Santos; Evdoxia Hatjiharissi; Vidit Munshi; Salvatore Venuta; Kenneth C Anderson; Steven P Treon; Nikhil C Munshi
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

7.  Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Alexandra Wikowicz; Evangelos Terpos; Marita Ziepert; Diana Nikolaus; Yin Yang; Natalie Fadle; Evi Regitz; Meletios A Dimopoulos; Steven P Treon; Zachary R Hunter; Michael Pfreundschuh
Journal:  Blood       Date:  2011-01-10       Impact factor: 22.113

8.  microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Xiaoying Jia; Abdel Kareem Azab; Patricia Maiso; Hai T Ngo; Feda Azab; Judith Runnels; Phong Quang; Irene M Ghobrial
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

9.  The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Xiaoying Jia; Judith Runnels; Hai T Ngo; Anne-Sophie Moreau; Mena Farag; Joel A Spencer; Costas M Pitsillides; Evdoxia Hatjiharissi; Aldo Roccaro; Garrett O'Sullivan; Douglas W McMillin; Daisy Moreno; Tanyel Kiziltepe; Ruben Carrasco; Steven P Treon; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

Review 10.  Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.

Authors:  Antonio Sacco; Aldo Roccaro; Irene M Ghobrial
Journal:  Oncotarget       Date:  2010-11
View more
  7 in total

1.  Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Authors:  C Baer; F Dicker; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

2.  PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.

Authors:  Mona Sobhani; Jahangir Abdi; Saha N Manujendra; Christine Chen; Hong Chang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 3.  MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.

Authors:  O Landgren; N Tageja
Journal:  Leukemia       Date:  2014-02-27       Impact factor: 11.528

4.  Primary Isolated Lymphoplasmacytic Lymphoma (LPL) of the Stomach: A Case Report.

Authors:  Hany S Attallah; Mufaddal Moonim; Paul Fields; David Wrench; Jessica Brady; N George Mikhaeel
Journal:  Am J Case Rep       Date:  2020-07-20

Review 5.  Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.

Authors:  Daniela Drandi; Philippe Decruyenaere; Martina Ferrante; Fritz Offner; Jo Vandesompele; Simone Ferrero
Journal:  Diagnostics (Basel)       Date:  2022-04-12

6.  Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.

Authors:  Juliette M Bouyssou; Chia-Jen Liu; Mark Bustoros; Romanos Sklavenitis-Pistofidis; Yosra Aljawai; Salomon Manier; Amir Yosef; Antonio Sacco; Katsutoshi Kokubun; Shokichi Tsukamoto; Adriana Perilla Glen; Daisy Huynh; Jorge J Castillo; Steven P Treon; Véronique Leblond; Olivier Hermine; Aldo M Roccaro; Irene M Ghobrial; Marzia Capelletti
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

7.  Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma.

Authors:  Sara Rodriguez; Jon Celay; Ibai Goicoechea; Cristina Jimenez; Cirino Botta; Maria-José Garcia-Barchino; Juan-Jose Garces; Marta Larrayoz; Susana Santos; Diego Alignani; Amaia Vilas-Zornoza; Cristina Perez; Sonia Garate; Sarai Sarvide; Aitziber Lopez; Hans-Christian Reinhardt; Yolanda R Carrasco; Isidro Sanchez-Garcia; Maria-Jose Larrayoz; Maria-Jose Calasanz; Carlos Panizo; Felipe Prosper; Jose-Maria Lamo-Espinosa; Marina Motta; Alessandra Tucci; Antonio Sacco; Massimo Gentile; Sara Duarte; Helena Vitoria; Catarina Geraldes; Artur Paiva; Noemi Puig; Ramon Garcia-Sanz; Aldo M Roccaro; Gema Fuerte; Jesus F San Miguel; Jose-Angel Martinez-Climent; Bruno Paiva
Journal:  Sci Adv       Date:  2022-01-19       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.